Notice of Change to Funding Opportunity: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)
Notice Number:
NOT-OD-23-141

Key Dates

Release Date:

June 20, 2023

Related Announcements

  • June 20, 2023 - Notice of Change to Funding Opportunity: RADx- UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional).  See Notice NOT-OD-23-138.
  • May 17, 2023 - Notice of NEI Participation in RFA-OD-23-051, "Emergency Award: RADx-UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional)". See Notice NOT-EY-23-007
  • May 2, 2023 - Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed). See Notice RFA-OD-23-050.
  • May 2, 2023 - Emergency Award: RADx- UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional).  See Notice RFA-OD-23-051
  • August 31, 2022 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
  • August 5, 2022 - Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This notice corrects RFA-OD-23-050  Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed) to remove the emergency designation and extend the review and award cycle dates.

Changes to the notice of funding opportunity (NOFO) are shown below:

Currently reads:

Title of funding opportunity:

Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)

Current key dates:

Application due dates: July 3, 2023

Review and award cycles:

Scientific Review Merit: August 2023

Advisory Council Review: Not Applicable

Earliest Start Date: September 2023

Expiration date: July 4, 2023

Section II. Award Information

Funds Available and Anticipated Number of Awards: The number of awards is contingent upon availability of funding and the submission of a sufficient number of meritorious applications. NIH estimates a commitment of $2,800,000M in FY 2023 for ~4-7 awards. Awards may be multi-year funded.

Award Budget: Application budgets are limited to a total of $275,000 direct costs over the two-year project period.

Award Project Period: The maximum project period is two years.

Section IV. Application and Submission Information

6. Funding Restrictions: All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Awards issued under this NOFO may be incrementally funded awards for each budget period with a project period of 2 years. NIH will not issue any awards under this NOFO for a single budget period for multiple years.

Modified to Read (changes shown in bold italics):

Title of funding opportunity: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)

Key dates:

Application due dates: July 3, 2023

Review and award cycles:

Scientific Review Merit: October 2023

Advisory Council Review: January 2024

Earliest Start Date: March 2024

Expiration date: July 4, 2023

Section II. Award Information

Funds Available and Anticipated Number of Awards: The number of awards is contingent upon availability of funding and the submission of a sufficient number of meritorious applications. NIH estimates a commitment of the following amounts in FY 2024: $1,500,000, 4-7 awards.

Award Budget: Application budgets are limited to a total of $275,000 direct costs over the two-year project period.

Award Project Period: The maximum project period is two years.

Section IV. Application and Submission Information

6. Funding Restrictions:

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement

Inquiries

Please direct all inquiries to:

Karen Nieves Lugo, PhD, MPH
National Institute on Minority Health and Health Disparities
karen.nieveslugo@nih.gov 
301-480-4727